Marrow stromal layers were used to investigate the potential role of negative regulators produced by the marrow microenvironment as one potential cause of hematopoietic suppression after chemotherapy and cytokines. Stromal layers were established from marrow of normal or prechemotherapy donors and breast cancer patients after hematological recovery from one cycle of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide and GM-CSF or PIXY321 (GM-
and increased incidence of graft failure after autologous marrow transplantation have also been linked to prior chemotherapy. [6] [7] [8] Similarly, low yields of CD34 + cells and hematopoietic progenitor/stem cells during peripheral blood mobilization regimens correlated with the type and timing of prior chemotherapy. [9] [10] [11] The causes for these deficiencies have not been ascertained.
The continuous replacement of blood cells in normal adults is provided by committed and primitive progenitor cells that are heterogeneous with respect to their selfrenewal, proliferative and differentiation capacities. [12] [13] [14] Normally, hematopoietic progenitors reside in the marrow, and blood cell production is regulated by complex interactions of progenitor cells with the marrow microenvironment. [15] [16] [17] The stromal cell layer, an adherent layer of cells that forms in marrow long-term cultures (LTC) simulates the marrow microenvironment and supports the maintenance and proliferation of hematopoietic progenitor cells. 15, 16 Previous results demonstrated that marrow from some groups of patients who recovered from high-dose chemotherapy or chemotherapy followed by autologous transplantation had decreased numbers of hematopoietic progenitors such as colony-forming units for granulocytes and macrophages (CFU-GM). [18] [19] [20] [21] [22] [23] . LTC were also shown to have a reduced capacity to maintain the production of CFU-GM and burst-forming units for erythroid cells (BFU-E). 7, [18] [19] [20] [21] [22] 24 Bone marrow injury was evident after recovery from the first cycle of chemotherapy and even when peripheral blood counts and the number of committed progenitors and CD34
+ cells in the marrow were within the normal range. 22 Hematopoietic stimulatory cytokines have not been shown to ameliorate suppressive or toxic effects of chemotherapy or radiation on the number of either committed or primitive hematopoietic progenitors in the marrow 22, 25, 26 and in some cases may have additional suppressive effects on marrow recovery. 22, 26 Damage to either the hematopoietic progenitor/stem cell compartment or the marrow microenvironment or both has been implicated as a potential cause for suppressive effects of bone marrow function observed after chemotherapy. 7, 19, 21, 23, 24, 26, 27 A variety of stimulatory and negative factors that regulate the proliferation and differentiation of hematopoietic progenitors are expressed in the marrow microenvironment. 6, [28] [29] [30] Two of the possible causes for hematopoietic deficiencies observed after chemotherapy are either a decrease in production of stimulatory factors or an increase in the production of inhibitory factors by the marrow microenvironment. For example, increased production of hematopoietic negative regulators such as TGF-␤, IFN-␥, IFN-␣, TNF-␣, and IL-4 was implicated as a cause for the reduced capacity of HIV and CMV infected stromal cell layers, and stromal cell layers of marrow from patients with some malignancies, to support hematopoiesis from normal donor hematopoietic progenitors. [31] [32] [33] [34] The purpose of the present study was to determine whether increases in TNF-␣, TGF-␤ or IL-4 from marrow stromal layers was a possible cause for the reduced capacity of post-chemotherapy LTC to maintain the production of committed progenitors.
Materials and methods

Normal donors and patients
Normal donors and patients were required to give informed consent as participants of National Cancer Institute Institutional Review Board approved protocols. Normal donors were not receiving any medication and had normal peripheral blood counts at the time of marrow harvest. , and was followed by either no cytokine, GM-CSF (sargramostim, Leukine; Immunex, Seattle, WA, USA) 250 g/m 2 daily subcutaneously, or PIXY321 (375 g/m 2 twice daily subcutaneously from days 5 to 19 of each 21 day cycle or until hematological recovery. 5 After the first cycle of FLAC, marrow was obtained from patients once their blood counts had recovered to an ANC Ͻ1.5 × 10 9 /l and platelets Ͻ90 × 10 9 /l, and cytokine administration was discontinued for at least 48 h. 22 Marrow was also obtained from one patient 1 year following five cycles of FLAC + PIXY321, and from another patient with Table 1 Recovery of committed and primitive progenitors in post-chemotherapy marrow CD34 + cells metastatic breast cancer approximately 6 weeks following high-dose cyclophosphamide 4 g/m 2 i.v. on day 1 and G-CSF 10 g/kg daily subcutaneous injection on day 2 and continued for 2-4 days after the total WBC was Ͼ2 × 10 9 /l.
Source of CD34
Preparation of cell suspensions
Bone marrow aspirates were obtained from the posterior iliac crests. Five to 20 ml of bone marrow were collected in a 20 ml syringe containing preservative-free heparin (Sigma, St Louis, MO, USA) and then diluted in Dulbecco's phosphate-buffered saline without Ca +2 or Mg
+2
(DPBS; GIBCO BRL, Gaithersburg, MD, USA) containing penicillin-streptomycin (GIBCO). Marrow cells with a density of р1.077 g/ml were collected and washed three times after separation on a Ficoll-sodium diatrizoate (Lymphocyte Separation Medium; Organon Teknika, Durham, NC, USA) gradient. A portion of the cells was resuspended to 2 × 10 6 cells/ml in enriched Iscove's modified Dulbecco's medium (IMDM) 35 with 10% fetal bovine serum (Hyclone, Logan, UT, USA) and incubated in tissue culture flasks at 37°C and with 5% CO 2 . The next day, nonadherent cells were collected and washed. Viable cell concentrations were determined by hemacytometer counts and trypan blue dye exclusion. Umbilical cord blood was collected and processed as previously described. 36 
Enrichment of CD34
+ bone marrow cells CD34 + cells were selected by positive immunomagnetic selection using a high-gradient magnetic separation column and MiniMacs CD34 progenitor cell isolation kit (Miltenyi Biotec, Auburn, CA, USA). The purity of the recovered cells was determined by staining with CD34 (anti-HPCA-2) phycoerythrin (PE; Becton Dickinson, San Jose, CA, USA), and flow cytometry analyses demonstrated that purity was у90%. CD34 + cells were suspended in 7.5% DMSO (Sigma) in 47% heat inactivated fetal bovine serum and IMDM, cryopreserved in a controlled rate freezer, and stored in the vapor phase of liquid nitrogen. Cells were quickly thawed in a 37°C water bath, washed twice with excess IMDM, incubated for 1.5-2 h at 37°C, 5% CO 2 , washed again, and counted.
Establishment of bone marrow stromal cell layers
Stromal cell layers were established basically as previously described 34, 37 by culturing 2 × 10 6 cells with a density of р1.077 g/ml in 2.0 cm 2 wells of Nunclone 4-Well Multidishes (Nunc, Naperville, IL, USA). The cells were diluted in 1 ml of Myeloid long term culture medium (Stem Cell Technologies, Vancouver, Canada) containing freshly prepared 1 × 10 -6 m hydrocortisone-21-hemisucccinate (Sigma) and incubated at 37°C with 5% CO 2 and room air. Weekly, 500 l of the medium and nonadherent cells were removed and replaced with 500 l of fresh medium. After 4 weeks, the stromal layers were exposed to 15 Gy of ␥-irradiation (1 Gy/min) from a 137 Cs Gammacell 40 irradiator. This dose of radiation eliminated progenitor cells surviving in the stromal cell layers (data not shown). For cytokine pretreatment studies the media were changed the next day, and DPBS or 20 ng/ml PIXY321 (Immunex) or GM-CSF (R&D Systems, Minneapolis, MN, USA) were added to the cultures. Two days later the layers were washed at least three times to remove cytokine; after an additional 3 days 2 × 10 4 CD34 + normal donor marrow cells were cocultured with the stromal layers. Effect of FLAC chemotherapy on production of CFU-GM and BFU-E in bone marrow long-term cultures (LTC). LTC were established from marrow obtained from patients prior to start of therapy and after hematological recovery from the first cycle of FLAC chemotherapy. Weekly, nonadherent and adherent cells were harvested and subcultured in methylcellulose supplemented with PHA-LCM and EPO to stimulate colony formation from CFU-GM and BFU-E. The number of CFU-GM and BFU-E in post-chemotherapy marrow used to establish LTC was either similar to or greater than the number in prechemotherapy marrows. The values are the median calculated from the percentage of CFU-GM and BFU-E from post-chemotherapy LTC relative to prechemotherapy LTC from the same patient (n = 13 for weeks 1 and 4; n = 11 for weeks 2 and 3; and n = 8 for week 5). *By Wilcoxon matched-pairs signed rank test of significance, the number of CFU-GM and BFU-E in post-chemotherapy LTC was significantly different (P Ͻ 0.05) from numbers in prechemotherapy LTC.
Coculture of normal donor CD34 + cells with stromal cell layers
For stromal contact cocultures, 1 or 2 × 10 4 CD34 + cells were placed directly on the irradiated stromal cell layers. From 1 to 4 weeks later, nonadherent and adherent cells were harvested from two LTC as previously described. 22, 34, 37 Briefly, the adherent cells were detached from the culture wells by incubating the cell layers at 37°C with 0.25% trypsin and 1 mm EDTA (GIBCO) or a 0.1% solution of type I collagenase (Sigma) prepared in DPBS without Ca counted, and then subcultured in methylcellulose with 10% PHA-LCM or with 10 ng/ml IL-3, 10 ng/ml GM-CSF and 50 ng/ml SCF (Stem Cell Technologies) to stimulate colony growth from CFU-GM. For BFU-E determinations, 3 U/ml of EPO were added to the methylcellulose. One ml of methylcellulose medium containing cells was placed in a 35-mm 2 gridded tissue culture dish (Nunc) and then maintained in a humidified 37°C incubator with 5% CO 2 and 95% room air. After 14 days, colonies containing у50 granulocytes or macrophages or both and colonies containing у50 erythroid cells were counted as derived from CFU-GM and BFU-E, respectively. In stromal noncontact cocultures 1-2 × 10 4 CD34 + cells in 6.5-mm nontissue culturetreated 0.1 mm pore Transwells (Costar, Cambridge, MA, USA) were placed over the irradiated stromal layers. After 1 week of incubation at 37°C and 5% CO 2 and 95% room air, cells in the Transwells were removed, washed, counted, and subcultured in methylcellulose for detection of CFU-GM. 
Limiting dilution assay for detection of long-term cultureinitiating cells (LTC-IC)
Long-term culture-initiating cells (LTC-IC) determinations were made by culturing marrow CD34
+ cells in limiting dilution over the M2-B104 murine stromal cell line (ATCC, Rockville, MD, USA) in wells of 96-well culture plates (Nunclone) as previously described. 38 Cells from the liquid cultures were washed and then diluted in Myelocult long term culture medium (Stem Cell Technologies) with 4 × 10 3 CD34 + cells/ml as the highest concentration and then diluted 1:1.6 for three to five more dilutions. Twenty wells with an established stromal cell layer were cocultured with 120 l of each cell dilution. Cultures were maintained in a humidified 37°C incubator with 5% CO 2 and 95% room air. Weekly, 60 l of medium and nonadherent cells were replaced with an equal volume of medium. After 5 weeks, the number of wells containing cobblestone areas of у20 translucent cells and the number of negative wells were determined and used to calculate the number of LTC-IC per liquid culture.
Antibody treatment of bone marrow cocultures
Neutralizing antibodies to TNF-␣ (goat IgG), TNF-␤ (goat IgG), IL-4 (goat IgG) and TGF-␤ (chicken IgG) (all from R&D Systems) were resuspended in Dulbecco's phosphate buffered saline (DPBS; GIBCO) with 0.1% deionized bovine serum albumin. Antibodies (20 g/ml) were added to stromal layers on day 0, 2 and 4 after coculture of CD34 + cells. 34 
Detection of TNF-␣ activity
Enzyme-linked immunoassays were used to detect TNF-␣ (Immunotech, Westbrook, ME, USA and R&D Systems), MIP-1␣ (R&D Systems), TGF-␤ (R&D Systems) and IFN-␥ (R&D Systems) activity in media from stromal layers. Some layers were incubated for 18 h with 10 g/ml of Lipopolysaccharide, E. coli (DIFCO, Detroit, MI, USA). Immunofluorescent microscopy was used to detect TNF-␣ on the surface of cells in the stromal layers. Cells from irradiated stromal layers were harvested, and 4 × 10 4 cells were subcultured in eight-chambered glass slides (Nunc). Three to 4 days later the cells were fixed in 2% formaldehyde and 0.1% gluteraldehyde for 10 min, washed three times in PBS, and then blocked with a 1:10 dilution of goat serum for 30 min at 37°C. Cells in each chamber were incubated for 1 h with 50 l of 500 g/ml neutralizing antibody to TNF-␣ (R&D Systems), washed three times for 5 min each in PBS, and then incubated for another hour at 37°C with 50 l of 5 g/ml anti-mouse IgG fluorescein antibody (Pierce, Rockford, IL, USA). After washing three times in PBS, the chambers and gaskets were removed from the slides, 15 l of Vectashield (Vector Laboratories, Burlington, CA, USA) were deposited on each stromal area. The slides were coverslipped, sealed, and stored at 4°C until ready to be viewed in a Leitz Orthoplan microscope (Leica, Deerfield, IL, USA).
Statistics
The Student's two-tailed t-test was used to test for significant differences between treated and untreated groups. Values between different groups were considered to be significantly different for P Ͻ 0.05. Nonparametric Wilcoxon matched-pairs rank test of significance was used to compare progenitor cell numbers in marrow prechemotherapy and post-chemotherapy LTC. 39 The multiplicity of LTC-IC was Neutralizing antibody to TNF-␣ promoted an increase in CFU-GM numbers in contact cocultures of post-chemotherapy P34 stromal layers and normal donor CD34 + cells (Table 6 ), but not in prechemotherapy P34 stromal layer cocultures (Table 5 ). NT = not tested; ND = not detectable. determined as described by St. Groth. 40 P values and a program which performs the calculations for LTC-IC were established using Microsoft Excel 5.0.
Results
Reduced progenitor cell numbers in marrow from patients treated with FLAC + PIXY321
Marrows obtained before chemotherapy and after hematological recovery from the first or second cycles of FLAC chemotherapy were enriched for CD34 + cells (у91% purity) and then cultured for detection of the committed progenitors, CFU-GM, and the primitive progenitors, LTC-IC. The frequency or number of CFU-GM from 1 × 10 4
CD34
+ cells was similar for cells from all three treatment arms and was not significantly different from the frequency in prechemotherapy or normal donor CD34
+ cells (Table 1) . Due to the reduced number of CD34 + cells in FLAC + PIXY321 marrows, there was, however, a reduced number of CFU-GM per ml of marrow aspirate that was not observed in FLAC + GM-CSF or FLAC + No cytokine marrows. The results also suggest that there was also a reduced number of LTC-IC in FLAC + PIXY321 marrows. These results indicate that PIXY321 administered after FLAC chemotherapy had suppressive effects on the recovery of both committed and primitive progenitors.
Decreased production of CFU-GM and BFU-E in postchemotherapy marrow long-term cultures (LTC)
LTC were used to assess the effect of chemotherapy on the production of the committed progenitors, CFU-GM and BFU-E, from more primitive hematopoietic progenitors. LTC were established from marrow obtained from 19 patients prior to chemotherapy and after their hematological recovery from the first or second cycle of FLAC chemotherapy. For 13 of those patients, the number of CFU-GM and BFU-E in post-chemotherapy marrow used to establish LTC was either similar to or greater than the number in prechemotherapy marrows (two out of two FLAC + No cytokine, seven out of eight FLAC + GM-CSF and four out of nine FLAC + PIXY321). The number of progenitors produced in LTC of pre-and post-chemotherapy marrows from those 13 patients was compared (Figure 1 ). Within the first 2 weeks, post-chemotherapy LTC had approximately 70% fewer progenitors than prechemotherapy LTC. During the 5 weeks of culture there were progressively fewer CFU-GM and BFU-E in post-chemotherapy LTC than in prechemotherapy LTC of marrow from the same patients. Results in a previous report, 22 demonstrated that postchemotherapy LTC had a reduced capacity for production of committed progenitors. Results in the present report further demonstrate a similar reduced capacity for production of committed progenitors even when the number of CFU-GM and BFU-E in marrow used to initiate LTC was similar in pre-and post-chemotherapy marrows.
Decreased CFU-GM production from normal donor CD34 + cells cocultured with post-chemotherapy stromal layers
Marrow stromal layers were used to determine whether changes in the marrow microenvironment were a potential cause for the reduced hematopoietic capacity of postchemotherapy LTC. Normal donor and prechemotherapy CD34 + cells were cocultured in contact with one normal donor and two prechemotherapy stromal layers ( Table 2 ). The number of CFU-GM detectable after 1 week of coculture was similar for all three stromal layers and varied depending on the source of CD34 + cells. The effect of postchemotherapy stromal layers on production of CFU-GM was therefore compared to normal donor or prechemotherapy stromal layers cocultured on the same day with the same source of CD34 + cells. The number of CFU-GM and BFU-E produced from normal donor CD34
+ cells cocultured with pre-and postchemotherapy stromal layers was determined. After 1 week, there were significantly fewer CFU-GM in both the adherent and nonadherent fraction of post-chemotherapy P25 stromal layer cocultures than in prechemotherapy P27 stromal layer cocultures (Figure 2 ). There was a 1.3-fold increase in total CFU-GM numbers in prechemotherapy P27 stromal cocultures, however, the number from P25 post-chemotherapy stromal cocultures had decreased by 45%. Similarly, there was a decreased production of BFU-E. Fewer CFU-GM and BFU-E were also observed in postchemotherapy P18 stromal layer cocultures than in prechemotherapy P20 stromal layer cocultures (Table 3) . In another experiment, after 4 weeks of coculture the total number of CFU-GM in P20, P25 and P31 post-chemotherapy stromal layer cocultures was only 21% (P = 0.004), 57% (P = 0.01) and 59% (P = 0.01), respectively, of the number in the normal donor stromal coculture (ie ND54) (Figure 3) . A reduced number of CFU-GM was observed in both 1 ( Figure 2 ) and 4 week P25 post-chemotherapy stromal cocultures cocultured with different CD34 + target cells and even when multiple recombinant factors were used to stimulate colony formation. These results demonstrate that some post-chemotherapy stromal layers had a reduced capacity to support the maintenance or production of committed progenitors.
Detection of TNF-␣ in post-chemotherapy LTC and stromal layer cocultures
In preliminary studies, culture supernatants from several LTC were collected 1 week after medium change and assayed for TNF-␣, MIP-1␣, TGF-␤, and IFN-␥; four factors shown to have some suppressive effects on in vitro hematopoiesis (Table 4) . Increased concentrations of TNF-␣ were detected in culture supernatants from two (ie P02 and P34) out of five post-chemotherapy stromal layers. For example, for P02, TNF-␣ increased from 4 Ϯ 0 pg/ml in prechemotherapy cultures to 116 Ϯ 7 pg/ml in culture supernatants from post-chemotherapy stromal layers. No increased concentrations of MIP-1␣, TGF-␤, or IFN-␥ were detected in post-chemotherapy LTC supernatants collected 1 week after media replacement. Neutralizing antibodies were added to stromal layer cocultures to determine whether TNF-␣ might be one cause for the suppressive effects of post-chemotherapy stromal layers. Treatment with anti-TNF-␣ had little effect on the number of CFU-GM from normal donor CD34
+ cells in noncontact cocultures with normal donor, pre-, or postchemotherapy stromal layers (Figure 4 ). In contrast, in post-chemotherapy stromal contact cocultures, anti-TNF-␣ treatment promoted a 1.4-fold increase in the total number of CFU-GM from normal donor CD34 + cells. A significant increase was observed for four out of five post-chemotherapy stromal layer cocultures. Neutralizing antibody to TNF-␤ (another goat IgG antibody) did not promote an increase in CFU-GM numbers in either pre- (Table 5) or post-chemotherapy (Table 6 ) stromal layer cocultures. Neither anti-TGF-␤ nor anti-LIF promoted an increase in CFU-GM numbers from P20 and P34 post-chemotherapy stromal layer cocultures (data not shown). Anti-IL-4 promoted an increase in CFU-GM numbers in one (ie, P38) out of three post-chemotherapy stromal layer cocultures (Table 6 ). These results suggest that increased levels of TNF-␣ and IL-4 might be one cause for the reduced capacity of post-chemotherapy stromal layers to support hematopoiesis.
Decreased numbers of CFU-GM from normal donor CD34 + cells cocultured with cytokine pretreated stromal layers
Immunofluorescence studies were done to determine whether GM-CSF and PIXY321 had an effect on the production or release of TNF-␣ from normal donor stromal layers ( Figure 5 ). Only low levels of TNF-␣ were detectable on the surfaces of cells in unstimulated cytokine pretreated and LPS-stimulated noncytokine pretreated stromal layers (Figure 5a and b) . Increased expression of TNF-␣ was observed on most cells after LPS stimulation of GM-CSF (Figure 5c and d) , PIXY321 (Figure 5e and f) and IL-3 pretreated stromal layers (data not shown). TNF-␣ was also detected in media from LPS-stimulated stromal layers ( Table 7) . The concentrations of TNF-␣ in media from GM-CSF and PIXY321 pretreated stromal layers, however, were approximately 1.6-to 5.7-fold greater than concentrations detected in noncytokine pretreated stromal layers. These results demonstrate that cells in GM-CSF and PIXY321 pretreated stromal layers had an increased capacity to release TNF-␣. The effect of cytokine pretreated stromal layers on the number of CFU-GM from normal donor CD34
+ cells was determined. In stromal noncontact cocultures, stromal layers preincubated with 2, 20 or 200 ng/ml of either GM-CSF or PIXY321 did not have suppressive effects on cell or CFU-GM numbers from CD34
+ target cells (n = 10, data not shown). In contrast, contact cocultures of normal donor CD34
+ cells with stromal layers pretreated with 20 ng/ml PIXY321 was reduced to 73 Ϯ 5% (mean Ϯ s.e.m. for n = 3 different donor stromal layers) of the number of CFU-GM in cocultures with noncytokine pretreated stromal layers (Table 8) . A reduced number of CFU-GM was also observed in cocultures with GM-CSF pretreated stromal layers of marrow from two out of four donors. Anti-TNF-␣ did not promote an increase in CFU-GM numbers from PIXY321 pretreated stromal layers. When there were fewer CFU-GM in GM-CSF pretreated stromal layer cocultures than in DPBS treated layers then there was an increase in CFU-GM numbers with anti-TNF-␣ treatment that was not observed in PIXY321 pretreated cultures (Figure 6a ). For the two other donor marrows, there were fewer and larger CFU-GM-derived colonies after anti-TNF-␣ treatment (Figure 6b ). Deterioration in integrity of GM-CSF pretreated stromal layers was partially prevented by treatment with anti-TNF-␣, but had no apparent effect on the deterioration of PIXY321 pretreated stromal layers. These results suggest that TNF-␣ mediated some of the hematopoietic suppressive effects of GM-CSF pretreated stromal layers, but was not the primary cause for the hematopoietic suppressive effects of PIXY321 pretreated stromal layers.
Discussion
In the present work, the effect of normal donor, GM-CSF and PIXY321 pretreated normal donor and patient postchemotherapy marrow stromal layers on the proliferation of normal donor CD34
+ cells was investigated. The results demonstrate that post-chemotherapy marrow stromal layers were deficient in supporting the production of granulocyte- macrophage and erythroid progenitors. Reduced numbers of CFU-GM were also detected in GM-CSF and PIXY321 pretreated stromal layers. The results indicate that TNF-␣ was one possible cause for some of the suppressive effects of post-chemotherapy and GM-CSF pretreated stromal layers, but not for the suppressive effects of PIXY321 pretreated stromal layers.
A previous study demonstrated that long-term cultures (LTC) of marrow obtained after FLAC chemotherapy produced 50-90% fewer erythroid and granulocyte-macrophage progenitors than prechemotherapy LTC from the same patients. 22 This decrease was observed even when the number of committed progenitors had recovered to prechemotherapy numbers and whether or not the patients had received either GM-CSF or PIXY321 to enhance their blood cell recovery. Damage to the progenitor/stem cell compartment or the marrow microenvironment or both has been implicated as potential causes for the reduced capacity of post-chemotherapy LTC to support hematopoiesis. 7, 19, 21, 23, 24, 26, 27 In the present study, stromal layers established from post-chemotherapy marrow were cocultured with normal * * * + cells with GM-CSF and PIXY321 pretreated stromal layers. Established stromal layers were irradiated to eliminate residual hematopoietic progenitors, and the following day the media were changed and DPBS or 20 ng/ml PIXY321 or GM-CSF was added to the cultures. Two days later the layers were washed at least three times to remove cytokine; after an additional 3 days, 2 × 10 4 CD34 + normal donor marrow cells were cocultured in direct contact with the stromal layers. On days 0, 2 and 4, DPBS or neutralizing antibody to TNF-␣ was added to the cocultures. On day 7, the nonadherent and adherent cells from stromal cocultures were collected, washed, counted and subcultured in methylcellulose supplemented with IL-3, GM-CSF and SCF to stimulate colony formation from CFU-GM. The values are the mean Ϯ s.d. number of CFU-GM calculated from three methylcellulose cultures each. (a) Experiment with reduced numbers of CFU-GM from GM-CSF pretreated stromal layers (ND54B stromal layer in Table 8 ). (b) Experiment with similar numbers of CFU-GM in untreated and GM-CSF pretreated stromal layers (ND58A stromal layer in Table 8 ). *By Student's two tailed t-test, significantly different (P Ͻ 0.05) from the number of CFU-GM detected in stromal layer cocultures with no cytokine or antibody treatment; **significantly different from number in no antibody treatment of similar pretreated groups. donor CD34
+ cells. For four out of five different patient marrows, the number of CFU-GM detected in contact postchemotherapy stromal layer cocultures was only 21-60% of the number in normal donor or prechemotherapy stromal layer cocultures. This decrease was observed after 1 and 4 weeks of culture. Results in the present study demonstrate that production of CFC was suppressed by post-chemotherapy stromal layers. For example, there was a 1.3-fold increase in the number of CFU-GM from umbilical cord blood CD34
+ cells cocultured for 1 week with prechemotherapy stromal layers. In contrast, the number of CFU-GM from the same target CD34
+ cells cocultured with postchemotherapy stromal layers was only 55% of the number at day 0. Although only a few patient stromal layers were evaluated, results in the present study corroborate observations reported by others showing that stromal layers of marrow exposed in vitro or in vivo to chemotherapeutic drugs were deficient in supporting the proliferation of myeloid as well as lymphoid precursors. 7, 19, 21, 41 Fewer CFU-GM were detected when normal donor CD34 + cells were cocultured in contact with PIXY321 pretreated stromal layers and 50% of GM-CSF pretreated stromal layers than were detected in untreated stromal layers. In addition to the effects of chemotherapy alone, some hematopoietic stimulatory factors have been shown to have further adverse effects on marrow content and function. 22, 25, 42 For example, cumulative production of CFU-GM in LTC of marrow obtained from patients still administered either GM-CSF or IL-3 after autologous marrow transplantation was only approximately one-third the number of CFU-GM produced in LTC of marrow from patients not administered cytokine after marrow transplantation. 42 This difference was no longer evident in LTC of marrow obtained from the same patients 4 weeks after cytokine treatment was discontinued. Whether the decreased production of CFC in the LTC was due to fewer hematopoietic progenitors in marrow from cytokine treated patients or the result of effects of the cytokines on function of the marrow microenvironment was not reported. Results in the present study demonstrate that both GM-CSF and PIXY321 had suppressive effects on in vitro hematopoiesis by their interaction with cells of the marrow microenvironment.
When normal donor CD34 + cells were cocultured in contact with PIXY321 pretreated stromal layers the number of CFU-GM was reduced to approximately 73% of the number in cocultures with untreated stromal layers. This decrease was not observed when CD34
+ target cells were placed in Transwells over the stromal layers (ie stromal noncontact cocultures). Using stromal noncontact cocultures, previous studies demonstrated that normal donor and HIV-infected marrow stromal layers produced factors that stimulated the proliferation of progenitors found in normal donor marrow, peripheral blood and umbilical cord blood cells. 35, 37, 43 Like the results in the present study, direct contact of the hematopoietic progenitors with the stromal layers was necessary to detect suppressive effects of the stromal layers on the maintenance and proliferation of hematopoietic progenitors. 37, 43 Fibroblasts, macrophages, endothelial cells, and adipocytes are the primary cell types found in stromal cell layers that develop in marrow long term cultures; a cellular composition that is similar to that observed for the in vivo marrow microenvironment. 15, 16 Marrow stromal layers express a multitude of factors that may be important in the positive and negative regulation of hematopoiesis. 16, 28, 29 Downregulation or upregulation of the expression or production of some of those factors has been implicated as a possible cause for the reduced capacity of stromal layers to support in vitro hematopoiesis that is observed with some malignancies, viral infections and poor marrow recovery after marrow transplantation. 19, [30] [31] [32] [33] [34] 44 Previous studies implicated TNF-␣, IL-4 and IFN-␣ as factors partially responsible for the reduced capacity of HIVinfected stromal layers to support the proliferation of normal donor CD34 + cells. 33, 34 Like the results in a previous study, 34 there was no significant effect of TNF-␣ neutralizing antibody treatment on the total number of CFU-GM produced in cocultures of normal donor CD34 + cells with normal donor or prechemotherapy stromal layers. In contrast, anti-TNF-␣ promoted a 1.3-fold to 1.6-fold significant increase in CFU-GM numbers in stromal layer cocultures for four out of five postchemotherapy marrows. This increase was observed for stromal layers of marrow from patients whether or not they had been administered cytokines after chemotherapy. An increased number of CFU-GM was observed after anti-IL-4 in only one out of three patient post-chemotherapy stromal layer cocultures. Interestingly, that patient developed prolonged thrombocytopenia and neutropenia during FLAC chemotherapy, and her blood counts were still below normal a year after treatment 27 (unpublished observations). These results suggest that one consequence of chemotherapy was an increase in production or release of TNF-␣ from cells of the marrow microenvironment.
Only low levels of TNF-␣ were detectable on the cell surface or in culture media from normal donor untreated or cytokine pretreated stromal layers. After LPS stimulation there was an increase in cell surface expression of TNF-␣ in GM-CSF and PIXY321 pretreated stromal layers. The TNF-␣ concentration in the media was 2-to 6-fold times higher in media from PIXY321 and GM-CSF pretreated stromal layers than in DPBS pretreated stromal layers. Others observed that in vivo or in vitro GM-CSF treatment was associated with an increase in TNF-␣. [45] [46] [47] [48] For example, Perkins et al 46 demonstrated that LPS-stimulated peripheral blood monocytes from patients administered GM-CSF released 8-fold more TNF-␣ than monocytes obtained from the same patients prior to GM-CSF. In the present study, some of the effects of in vivo administered GM-CSF could be reproduced by treating stromal cell layers with the cytokine in vitro. Macrophages and monocytes contain pools of mRNA for TNF-␣ and the increase in TNF-␣ after stimulation with LPS is the result of accelerated gene transcription and translation of stored, as well as new mRNA. 49 One consequence of chemotherapy and cytokine treatment may be an increase in levels of TNF-␣ mRNA that are rapidly expressed in response to LPS or other factors produced by stromal layers (for example, IL-1) or CD34 + target cells. When the number of CFU-GM from normal donor CD34 + was reduced in GM-CSF pretreated stromal layer cocultures, TNF-␣ antibody treatment promoted an increase to the number observed in untreated stromal cocultures. Anti-TNF-␣ however, promoted a reduction in total number, but an increase in the number of large colonies (many were macroscopic) when the number of CFU-GM was not reduced in untreated GM-CSF pretreated stromal layers. In addition to its inhibitory effects, TNF-␣ has been shown also to have stimulatory effects on in vitro hematopoiesis, and the results are dependent upon the cell lineage and maturation stage of the hematopoietic progenitors. 50, 51 In addition, TNF-␣ stimulates the release of other factors. [52] [53] [54] The variable effects of GM-CSF pretreated stromal layers with and without treatment with anti-TNF-␣ on the number and proliferative capacity of CFU-GM may reflect some of the different effects of TNF-␣ on populations of mature and primitive progenitors and stromal cells.
In contrast to the effects observed in GM-CSF pretreated stromal layer cocultures, TNF-␣ antibody treatment had no effect on the reduced number of CFU-GM observed in PIXY321 pretreated stromal layer cocultures. Similarly, deterioration in integrity of GM-CSF pretreated stromal layers was partially prevented by treatment with anti-TNF-␣, but neither anti-TNF-␣ nor anti-IL-4 treatment delayed the deterioration of PIXY321 pretreated stromal layers. These results indicate that other factors or conditions were responsible for the inhibitory effects of PIXY321 pretreated stromal layers. In addition to possible upregulation of other known or unknown negative regulators of hematopoiesis, other causes for the negative effects of PIXY321 pretreatment include insufficient levels of membrane bound stimulatory or survival factors with alterations in extracellular matrix and hematopoietic progenitor cell interactions. 16, 17, 31 Results in the present report demonstrate that postchemotherapy as well as GM-CSF and PIXY321 pretreated marrow stromal layers are deficient in their ability to support hematopoiesis from normal donor CD34 + cells. The results also indicate that an increase in release or production of TNF-␣ is one cause for the early hematopoietic suppressive effects of post-chemotherapy and GM-CSF pretreated stromal layers. TNF-␣ is a multifunctional factor that has direct effects on hematopoietic progenitors. 51 However, either alone or in combination with other factors, TNF-␣ also induces the release or production of IP-10, Mig, IL-8 and MIP-1␣ from monocytes/macrophages, fibroblasts, or endothelial cells, 52, 53 three of the cell types that comprise the marrow microenvironment. 15, 16 Mig (monokine inducible by interferon-␥), MIP-1␣, (monokine inducible by interfer-␥) on IP-10 and IL-8 are several of the chemokines shown to suppress the proliferation or production of hematopoietic progenitors. 38, [55] [56] What role these chemokines may have in producing the suppressive effects of post-chemotherapy and cytokine pretreated stromal layers is not known. Further defining the mechanisms responsible for the deficiencies in the functional integrity of the marrow microenvironment observed after chemotherapy and cytokine treatment may be important in understanding the causes underlying the atypical hematopoiesis observed after dose-intensive chemotherapy and autologous transplantation.
